Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors.
Open Access
- 15 May 1997
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 99 (10), 2538-2544
- https://doi.org/10.1172/jci119438
Abstract
We have investigated the metabolic actions of recombinant human IGF-1 in mice genetically deficient of insulin receptors (IR-/-). After intraperitoneal administration, IGF-1 caused a prompt and sustained decrease of plasma glucose levels in IR-/- mice. Plasma free fatty acid concentrations were unaffected. Interestingly, the effects of IGF-1 were identical in normal mice (IR+/+) and in IR-/- mice. Despite decreased glucose levels, IR-/- mice treated with IGF-1 died within 2-3 d of birth, like sham-treated IR-/- controls. In skeletal muscle, IGF-1 treatment caused phosphorylation of IGF-1 receptors and increased the levels of the phosphatidylinositol-3-kinase p85 subunit detected in antiphosphotyrosine immunoprecipitates, consistent with the possibility that IGF-1 stimulates glucose uptake in a phosphatidylinositol-3-kinase-dependent manner. IGF-1 receptor phosphorylation and coimmunoprecipitation of phosphatidylinositol3-kinase by antiphosphotyrosine antibodies was also observed in liver, and was associated with a decrease in mRNA levels of the key gluconeogenetic enzyme phosphoenolpyruvate carboxykinase. Thus, the effect of IGF-1 on plasma glucose levels may be accounted for by increased peripheral glucose use and by inhibition of hepatic gluconeogenesis. These data indicate that IGF-1 can mimic insulin's effects on glucose metabolism by acting through its own receptor. The failure of IGF-1 to rescue the lethal phenotype due to lack of insulin receptors suggests that IGF-1 receptors cannot effectively mediate all the metabolic actions of insulin receptors.Keywords
This publication has 51 references indexed in Scilit:
- Early neonatal death in mice homozygous for a null allele of the insulin receptor geneNature Genetics, 1996
- Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults.JCI Insight, 1994
- The IRS-1 signaling systemCurrent Opinion in Genetics & Development, 1994
- Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans.JCI Insight, 1993
- Treatment of type A insulin resistance with insulin-like growth factor-IThe Lancet, 1993
- A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans.JCI Insight, 1993
- Insulin/IGF-1 hybrid receptors: Implications for the dominant-negative phenotype in syndromes of insulin resistanceJournal of Cellular Biochemistry, 1992
- Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver.JCI Insight, 1988
- Short-Term Metabolic Effects of Recombinant Human Insulin-like Growth Factor I in Healthy AdultsNew England Journal of Medicine, 1987
- Purification and characterization of the receptor for insulin-like growth factor IBiochemistry, 1986